| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 2,534.7 | 2,645.5 | 2,431 | 2,465.8 |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 674.4 | 605 | 629.3 | 638.7 |
| Research and development | 436.1 | 399 | 434.1 | 542.7 |
| Acquired in-process research and development, upfront and milestone expense | 2.1 | 46.6 | 200.7 | - |
| Selling, general and administrative | 594.8 | 583.8 | 572.5 | 588.4 |
| Amortization and impairment of acquired intangible assets | 135.7 | 130.9 | 111.8 | 130.3 |
| Collaboration profit sharing/(loss reimbursement) | 87.2 | 75 | 58.1 | 69.3 |
| Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease) | 5.6 | 13.2 | 9.6 | 23.8 |
| Restructuring charges | 7.4 | -0.7 | 35.3 | 6.8 |
| Gain on sale of priority review voucher, net | 0 | 0 | - | 0 |
| Other (income) expense, net | -34.1 | -48.7 | -68.4 | -14.8 |
| Total cost and expense | 1,977.4 | 1,901.5 | 2,119.8 | 2,014.8 |
| Income before income tax (benefit) expense | 557.3 | 744 | 311.2 | 451 |
| Income tax (benefit) expense | 90.8 | 109.2 | 70.7 | 62.5 |
| Net income (loss) | - | - | - | 388.5 |
| Netincome (loss) attributable to noncontrolling interests, netoftax | - | - | - | 0 |
| Net income attributable to biogen inc | 466.5 | 634.8 | 240.5 | 388.5 |
| Basic earnings per share attributable to biogen inc. (in usd per share) | 3.18 | 4.33 | 1.65 | 2.67 |
| Basic earnings per share attributable to biogen inc. (in usd per share) | 146,600,000 | 146,500,000 | 146,100,000 | 145,700,000 |
| Diluted earnings per share attributable to biogen inc. (in usd per share) | 3.17 | 4.33 | 1.64 | 2.66 |
| Diluted earnings per share attributable to biogen inc. (in usd per share) | 147,100,000 | 146,700,000 | 146,600,000 | 146,100,000 |
BIOGEN INC. (BIIB)
BIOGEN INC. (BIIB)